AI Article Synopsis
- Dermatomyositis (DM) is a rare autoimmune disease that primarily affects the skin and can involve muscles, with new classification systems recognizing skin-dominant forms.
- Recent research has improved our understanding of the disease’s mechanisms and the role of specific autoantibodies, leading to the development of new treatments.
- This report focuses on recent advancements in treatments and outcome measures for DM, particularly from a dermatological perspective.
Article Abstract
Dermatomyositis (DM) is a rare autoimmune connective tissue disease with characteristic skin manifestations and possible muscle involvement. Recent advances in classification system to include skin-predominant subtypes, understanding underlying pathogenic mechanisms and the relationship between clinical phenotypes and myositis-specific autoantibodies have led to development of novel therapeutic options. This corresponds with efforts to develop better outcome measures to accurately catch the patients' current disease status and treatment-induced improvements. This report will review the updates in newer treatments and outcome measures of DM, specifically from a dermatologic point of view.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439981 | PMC |
| http://dx.doi.org/10.5021/ad.24.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!